Status:
COMPLETED
Seroquel (Quetiapine Fumarate) InPractice Evaluation Programme
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
Brief Summary
Patients eligible for entry into the study have a diagnosis of schizophrenia defined by Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria and of a chronic or sub-c...
Eligibility Criteria
Inclusion
- To assess at baseline and after treatment administration the severity of the illness in patients with schizophrenia, using the scores obtained after the application of the CGI scale
- To assess the changes in symptoms of patients treated with Seroquel for 24 weeks, using BPRS (Brief Psychiatry Rating Scale) as measuring tool
Exclusion
- All the patients who have a known hypersensitivity to Seroquel /quetiapine or any of its excipients will not be included in this study.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
1387 Patients enrolled
Trial Details
Trial ID
NCT00921362
Start Date
May 1 2006
End Date
January 1 2007
Last Update
June 16 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.